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ABSTRACT Current efforts toward human immunodeficiency virus (HIV) eradication in-
clude approaches to augment immune recognition and elimination of persistently in-
fected cells following latency reversal. Natural killer (NK) cells, the main effectors of the
innate immune system, recognize and clear targets using different mechanisms than
CD8 T cells, offering an alternative or complementary approach for HIV clearance strat-
egies. We assessed the impact of interleukin 15 (IL-15) treatment on NK cell function
and the potential for stimulated NK cells to clear the HIV reservoir. We measured NK cell
receptor expression, antibody-dependent cell-mediated cytotoxicity (ADCC), cytotoxicity,
interferon gamma (IFN-) production, and antiviral activity in autologous HIV replication
systems. All NK cell functions were uniformly improved by IL-15, and, more importantly,
IL-15-treated NK cells were able to clear latently HIV-infected cells after exposure to vori-
nostat, a clinically relevant latency-reversing agent. We also demonstrate that NK cells
from HIV-infected individuals aviremic on antiretroviral therapy can be efficiently stimu-
lated with IL-15. Our work opens a promising line of investigation leading to future im-
munotherapies to clear persistent HIV infection using NK cells.
IMPORTANCE In the search for an HIV cure, strategies to enhance immune function
to allow recognition and clearance of HIV-infected cells following latency reversal
are being evaluated. Natural killer (NK) cells possess characteristics that can be ex-
ploited for immunotherapy against persistent HIV infection. We demonstrate that NK
cells from HIV-positive donors can be strongly stimulated with IL-15, improving their
antiviral and cytotoxic potential and, more importantly, clearing HIV-infected cells af-
ter latency reversal with a clinically relevant drug. Our results encourage further in-
vestigation to design NK cell-based immunotherapies to achieve HIV eradication.
KEYWORDS natural killer cells, HIV, latency reversal, HIV eradication,
immunotherapy, vorinostat, VOR, SAHA, immune function, IL-15, shock and kill, kick
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The immune system is not capable of clearing human immunodeficiency virus (HIV)infection, and thus, even in the presence of fully suppressive antiretroviral therapy
(ART), infection is chronic. However, in recent years, significant progress has been made
in strategies to disrupt the viral latent reservoir, promoting new efforts toward virus
clearance or cure (1–3). Awakening the latent reservoir of persistent infection could
represent the first step in HIV eradication therapy, but clearance of infection requires a
second step involving a potent and efficient immune response. This combined strategy
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faces challenges, such as insufficient number and function of HIV-specific CD8 T cells 
(4–6), dispersed and scarce HIV antigen (Ag) expression in latently infected cells, and 
selection of virus populations poorly recognized by CD8 T cells (7–9). Therefore, 
alternative or complementary immune strategies should be pursued. Here, we model 
the ability to augment natural killer (NK) cell function in autologous HIV-infected-donor 
cell systems, demonstrating the potential to fill this unmet need.
NK cells are the main effectors of the innate immune system. They are the first line 
of defense against viral infections and also play an important role in more advanced 
stages of infection (10). Although controversial, evidence of viral evolution toward NK 
cell escape suggests that these cells exert specific immunological pressure on HIV (11, 
12). NK cells can eliminate HIV-infected cells by antibody-dependent cell-mediated 
cytotoxicity (ADCC), by direct lysis via the release of cytotoxic granules, and by 
facilitating priming of the adaptive immune response. Activation of NK cells is governed 
by the balance of positive signals via the recognition of cellular stress markers on the 
surfaces of infected or malignant cells and negative signals received primarily through 
killer cell immunoglobulin-like receptors (KIRs) engaging the major histocompatibility 
complex (MHC). It is especially interesting that HIV downregulates MHC class I expres-
sion on the surfaces of infected cells, thereby escaping recognition and lysis by CD8 
T cells but, conversely, rendering it more susceptible to NK cell-mediated clearance (13). 
In addition, lymph nodes are a major anatomic HIV reservoir (14), and CD8 effectors 
may be relatively excluded from lymphoid follicles, making them a potential sanctuary 
for persistent infection (15). Recently, it has been reported that NK cells can accumulate 
in the follicles of secondary lymphoid organs in simian immunodeficiency virus (SIV)-
infected African green monkeys (AGMs), natural controllers of SIV replication (16). These 
findings encourage investigation of NK cell-based immunotherapies for HIV eradication.
Cytokines play a decisive role in activating NK cells by enhancing their cytotoxic 
potential (17). Interleukin 15 (IL-15) is a potent enhancer of NK cytotoxic function and 
is under study in oncology, given its potential to improve the clearance of malignant 
cells (18). In the present work, we analyzed the potential of cytokine-stimulated NK cells 
to recognize and clear latently HIV-infected cells after latency reversal and performed 
a comprehensive characterization of the impact of cytokine treatment on NK cell 
function. We demonstrate that upon treatment with IL-15, NK cells improve their 
capacity to target and clear HIV-infected cells.
RESULTS
IL-15 treatment improves antiviral activity of NK cells. HIV-infected CD4 T cells 
derived from 8 donors were superinfected with the laboratory strain JR-CSF, and cells 
from 6 additional donors were infected with autologous reservoir virus (AR). Infection 
using AR is relevant, given the diversity of viral isolates within and between donors, as 
well as the potential for viral isolates that have evolved to escape immune responses. 
Pooled analysis of all the donors showed that at a 1:1 effector/target cell (E:T) ratio, 
autologous NK cells significantly reduced viral replication, from 100% under the target-
alone condition to 31.2% (standard error of the mean [SEM], 4.3%; P  0.0002), while 
IL-15 stimulation of NK cells further decreased viral replication (4.8% [SEM, 1.3%; P  
0.0002]), with significant differences between untreated and IL-15-treated NK cells (P  
0.0005). Virus reduction was also seen at a 1:10 E:T ratio for both untreated NK cells and 
IL-15-stimulated cells (65% [SEM, 6.3%; P  0.0004] and 44.3% [SEM, 4,8%; P  0.0001], 
respectively), and again, IL-15 significantly improved antiviral activity (P  0.008). 
Finally, at a 1:100 ratio, only IL-15-stimulated cells exerted a significant impact on virus 
production (79.5% [SEM, 5.5%; P  0.02]) (Fig. 1A). When the experiments were 
analyzed according to the viral isolate used for infection (JR-CSF or AR), the patterns of 
inhibition were comparable between the viruses (Fig. 1B).
Intracellular p24 (Fig. 1C) was measured in 5 experiments, 2 of them performed with 
cells from HIV-negative donors and the other 3 with cells from HIV-infected donors. 
After 5 days in culture, the percentage of live p24-positive CD4 T cells was reduced 
from a mean of 9.12% (SEM, 0.07%) under target-alone conditions to 7.23% (SEM,
FIG 1 IL-15 improves the antiviral activity of NK cells from ART-treated HIV-infected donors. (A) Viral replication measured as HIV gag p24 antigen in the
supernatants of 7-day cultures with only infected CD4 T cells (Targets alone) or in the presence of NK cells at different effector/target cell ratios. UT, untreated.
The red asterisks indicate statistically significant differences compared to targets alone, and black asterisks indicate differences between untreated and
IL-15-stimulated NK cells (n  14). (B) Viral replication in viral inhibition assays performed with JR-CSF superinfection (n  8) or autologous reservoir virus (n 
6). Wilcoxon matched-pairs signed-rank test. *, P  0.05; **, P  0.01; ***, P  0.001. The error bars indicate standard error of the mean (SEM). (C) Representative
flow cytometry plots of intracellular p24 in cells from one donor gated on the CD3 population of the live fraction. (D) Proportion of live CD4 T cells positive
for intracellular p24 staining. Coculture of infected CD4 cells with IL-15-treated NK cells significantly reduced the proportion of live CD4 T cells containing p24
antigen after 5 days in culture. The orange circles correspond to cells from HIV-negative donors (n  2), and the purple squares correspond to cells from aviremic
HIV-positive donors (n  3). Mann-Whitney U test. (E) Interaction of an NK cell with an infected CD4 T cell visualized with ImageStreamX.
0.71%) when target cells were cultured with NK cells, and further, to 5.25% (SEM, 
0.60%), when NK cells were treated with IL-15 (Fig. 1D). Finally, we visualized cells from 
a p24 intracellular-staining experiment using Amnis ImageStreamX and found several 
interactions between NK cells (marked with CD56-fluorescein isothiocyanate [FITC]) and 
HIV-infected target cells (CD3-allophycocyanin [APC] to identify targets and p24-
phycoerythrin [PE] to detect infection) (Fig. 1E).
Cytotoxicity and IFN- production after IL-15 stimulation. NK cell cytotoxicity 
was evaluated through the expression of the degranulation marker CD107a. NK cells, 
with or without IL-15 stimulation, were cultured in the presence of either autologous 
superinfected CD4 cells or the cell line K562. After coculture with K562 cells, 36.9%
(SEM, 2.5%) of NK cells degranulated and became CD107a compared to 58.1% (SEM, 
2.8%) of the IL-15-stimulated NK cells (P  0.0001) (Fig. 2A, left). IL-15 stimulation also
FIG 2 IL-15 increases the cytotoxic function of NK cells. (A) (Left and middle) Degranulation of NK cells measured by CD107a expression after coculture with
the cell line K562 or autologous HIV-superinfected CD4 T cells (n  21 and n  8, respectively). (Right) IFN- production after coculture with K562 cells
measured by intracellular staining (n  17). Wilcoxon matched-pairs signed-rank test. (B) (Left and middle) Comparison between degranulation and IFN-
production in NK cells from HIV-negative or HIV-positive donors. (Right) Fold change (IL-15/untreated) of CD107a expression and IFN- production in
HIV-negative and HIV-positive donors. Mann-Whitney test. The orange circles correspond to cells from HIV-negative donors, and the purple squares correspond
to cells from aviremic HIV-positive donors. The error bars indicate SEM.
significantly improved NK cell degranulation in the presence of autologous HIV-
superinfected CD4 T cells, increasing from a mean of 14.5% (SEM, 3.4%) to 28.7%
(SEM, 4.6%) (P  0.01) (Fig. 2A, middle). IL-15 also enhanced NK cell IFN- production 
(P  0.0001), measured by intracellular staining, from an average of 13.3% (SEM, 2.2%) 
of NK cells producing IFN- to 43% (SEM, 4.2%) (Fig. 2A right). We also compared the 
performance of NK cells isolated from HIV-negative and HIV-positive donors. NK cells 
from HIV-negative and HIV-positive individuals degranulated to equal extents, both 
without treatment and after IL-15 stimulation. However, NK cell baseline IFN- produc-
tion was impaired in aviremic HIV-positive donors (P  0.0008), but interestingly, IL-15 
restored the capacity of NK cells to produce IFN- to the same level as HIV-negative 
individuals (Fig. 2B).
Impact of other cytokines on NK cell-mediated cytotoxicity. Given that other 
cytokines may surpass or augment the effect of IL-15 on NK cell immune function, we 
performed cytotoxicity assays measuring degranulation and IFN- production after 
coculturing K562 cells with NK cells treated with IL-15, IL-12, IL-18, or IL-21 (25 ng/ml) 
alone or in combination (Fig. 3). Stimulation of NK cells with any of the cytokines alone 
or in combination provided a significant increase in degranulation against K562 cells 
compared to untreated NK cells (P  0.03). However, IL-15 stimulation proved to 
augment the function more than treatment with IL-12, IL-18, or IL-21 (P  0.03), and no 
differences were found between IL-15 alone and IL-15 in combination with any or all of 
the other cytokines. When degranulation was measured in the absence of a target cell 
line (NK alone), we observed a modest increase in nonspecific degranulation when NK 
cells were stimulated with any of the other cytokines in addition to IL-15, reaching
FIG 3 NK cell-mediated cytotoxicity after treatment with different cytokines. The graphs show the proportions of
NK cells degranulating or producing IFN- in the presence of K562 cells (red squares) or in the absence of target
cells (green circles) after stimulation with different cytokines or combinations, as indicated in the table below.
Degranulation after culture with the cell line K562 showed a target-specific increase in cytotoxicity after stimulation
with any of the cytokines or the studied combinations (P  0.03). However, IL-15 showed better stimulation than
IL-12, IL-18, or IL-21 (P  0.03), and no difference was found between IL-15 alone and IL-15 in addition to any of
the other cytokines (P, NS). IFN- production upon culture with K562 cells is increased after stimulation with IL-15
or IL-12 alone or any of the cytokine combinations (P  0.03). The IL-15 effect was improved when IL-12 or IL-12
and IL-18 were included. However, IFN- production in the absence of target cells (NK alone) also increased after
IL-12 or IL-12 and IL-18 addition to IL-15, indicating nonspecific activation. Wilcoxon matched-pairs signed-rank
test. The error bars indicate SEM.
statistical significance for IL-15 plus IL-12, IL-15 plus IL-18, IL-15 plus IL-21, and IL-15 
plus IL-12 plus IL-21. NK cell production of IFN- after coculture with the cell line K562 
was increased when the cells were treated with IL-15 or IL-12 alone, as well as with IL-15 
in combination with any of the other cytokines (P  0.03), but no effect was observed 
upon stimulation with IL-18 or IL-21 alone. Moreover, addition of IL-12 and IL-12 plus 
IL-18 to IL-15 significantly increased IFN- production compared to IL-15 alone (P  
0.03). However, in the absence of target cells, addition of IL-12 or IL-12 plus IL-18 to 
IL-15 also produced a significant increase (P  0.03) compared to IL-15 alone. Thus, 
combination of other cytokines with IL-15, especially IL-12, might improve NK cell 
capacity to produce IFN-, but these cytokine combinations were associated with 
nonspecific effects, as shown by the significant increase in IFN- production in the 
absence of target cells, supporting further exploration of IL-15 alone.
ADCC activity of NK cells is enhanced after IL-15 stimulation. We evaluated 
whether IL-15 stimulation of NK cells had an effect on ADCC activity, using HIV-infected 
CEM.NKRCCR5 cells as targets in a luciferase assay. NK cells were isolated from 6 
HIV-negative and 6 HIV-positive ART-treated aviremic donors. Untreated or IL-15-
treated NK cells were tested against subtype C HIV-1 TV-1-infected target cells in the 
presence of serial dilutions of plasma from an HIV-infected participant. In both groups, 
we observed very similar statistically significant increases in target-specific killing when 
NK cells were stimulated with IL-15 (Fig. 4A) (P  0.001). Comparison of the responses 
from all the participants was also performed, using antibody titers (Fig. 4B) and the area 
under the curve (Fig. 4C), which revealed statistically significant differences between 
the responses obtained with untreated and IL-15-treated effector cells (P  0.0005). We 
did not observe statistically significant differences between the ADCC activities of 
HIV-negative and HIV-positive donors when we compared the results under untreated 
and IL-15-treated conditions.
IL-15-stimulated NK cells recognize and clear latently HIV-infected cells after 
reactivation. A modified viral outgrowth assay was used to assess the ability of NK cells 
to recognize and clear latently infected cells once they were induced to emerge from 
latency and reexpress viral antigen. The goal of this assay is to mimic the conditions 
that might exist in a future clinical experiment in which latency reversal agents might 
induce antigen expression without robust viral production or cellular activation. Resting 
CD4 T cells were isolated from HIV-positive donors and either activated using phy-
tohemagglutinin (PHA) as a positive control of maximal mitogen stimulation or treated
FIG 4 ADCC improves after IL-15 stimulation of NK cells. NK cells were cultured with TV-1-infected 
CEM.NKR cells in the presence of HIV-negative or A300 (HIV-positive) plasma for 6 h, and specific target 
killing was recorded using different plasma dilutions. (A) Mean antibody-mediated specific killing with 
untreated NK cells or after overnight IL-15 stimulation using different plasma dilutions. Cytokine 
treatment improved ADCC activity in both HIV-negative (n  6) and HIV-positive (n  6) donors. Means 
with SEM are shown. (B) Antibody titers observed with untreated/treated NK cells (n  12). (C) Areas 
under the curve at different plasma dilutions with untreated NK and IL-15-stimulated NK cells (n  12). 
The orange circles correspond to cells from HIV-negative donors, and the purple squares correspond to 
cells from ART-treated aviremic HIV-positive donors. Wilcoxon matched-pairs signed-rank test.
with the histone deacetylase (HDAC) inhibitor vorinostat (VOR) (also known as SAHA) 
under conditions known to parallel clinical administration of the drug (1). At the end of 
the culture, the supernatants were harvested, and viral production was measured by 
p24 enzyme-linked immunosorbent assay (ELISA), recording the number of wells in 
which virus was recovered, regardless of the quantity of p24 measured. The underlying 
assumption was that each well would possess one or fewer infected cells and that a 
decrease in the frequency of wells with detectable p24 reflected clearance of the 
infected cells.
When resting CD4 T cells were reactivated with PHA, a decrease in the number of 
HIV-positive wells was observed when NK cells were added to the culture (P, not 
significant [NS]) (Fig. 5A, left panel), with a more pronounced reduction when the NK 
cells were first stimulated with IL-15 (P  0.031). Of more clinical relevance, when 
vorinostat was used to reverse latency, IL-15-stimulated NK cells significantly reduced 
the number of p24 HIV wells (P  0.015), with significant differences between 
untreated and IL-15-treated NK cells (P  0.013) (Fig. 5A, right panel).
Next, we introduced an important modification of the latency clearance assay by 
removing NK effector cells after the initial 24 h of coculture and prior to the addition 
of allogeneic uninfected target cells. Using this modification, reduction of wells with 
detectable p24 could be confidently associated with clearance of reactivated CD4 T 
cells rather than with inhibition of viral spread or feeder cell killing. We performed this 
modified latency clearance assay with IL-15-stimulated NK cells from 5 donors. The 
efficiency of CD56 cell depletion was 98% in all cases. In these experiments, we also 
observed a consistent decline in the number of positive wells when IL-15-treated NK 
cells were cocultured with resting CD4 cells, confirming that NK cell-mediated clearance 
takes place before the addition of feeders (Fig. 5B). In addition, annexin V binding was 
evaluated after 24-h culture of VOR-treated CD4 T cells in the presence or absence of
IL-15-stimulated NK cells to confirm that nonspecific cell killing was not responsible for
the observed virus clearance (5% annexinV-positive CD4 T cells).
Impact of IL-15 exposure on activating receptor expression in NK cells. Acti-
vating NK cell receptor expression was analyzed to explore the impact of IL-15
exposure. The panel included CD16, DNAM-1, NKG2D, NKp30, and NKp46. IL-15 stim-
ulation did not impact expression of CD16 or DNAM-1 but significantly increased the
expression of NKG2D and NKp30 (P  0.03). Interestingly, IL-15 exposure also produced
a significant down-modulation of NKp46 (P  0.03), as shown in Fig. 6.
DISCUSSION
The enhancement of the innate antiviral activity of NK cells is a viable adjunctive
clinical strategy that may be employed in efforts to clear persistent HIV infection. In the
present work, we demonstrate the ability of IL-15 stimulation to enhance NK cell
function in the context of HIV. Uniformly, IL-15 augmented NK cell function, improving
degranulation, ADCC activity, IFN- production, and direct antiviral activity in actively
replicating HIV cultures. Of most significance, IL-15-treated NK cells recognized and
cleared latently HIV-infected cells following a clinically achievable exposure to the
latency-reversing agent vorinostat.
Immunological strategies in the field of HIV eradication have focused on HIV-specific
cytotoxic T lymphocytes (CTLs) (19–21), although recently, interest in NK cells has
emerged. The capacity of NK cells to produce IFN- and upregulate NKp30 and NKp46
has been inversely associated with viral reservoir size (22), and HIV DNA decline was
FIG 5 Latency clearance assay. (A) Resting CD4 T cells were incubated with PHA or VOR for 24 h, cocultured with or without autologous
NK cells at an E:T ratio of 1:10 for another 24 h, and plated in 12 replicates in the presence of feeders for 19 days, refreshing the medium
every 3 or 4 days. The supernatant was assayed for p24 ELISA to assess the presence of HIV replication. The graphs show the numbers
of wells in which p24 was detected at day 19, with a different color for each donor. (Left) Reactivation with PHA (n  6). (Right)
Reactivation with 335 nM VOR (n  8). Wilcoxon matched-pairs signed-rank test. (B) Latency clearance assays in which NK cells were
depleted after the initial 24 h of coculture with VOR-reactivated CD4 T cells (n  5). IL-15-stimulated NK cells reduced the number of
HIV wells during the first 24 h of coculture with VOR-reactivated CD4 T cells. The error bars indicate SEM.
FIG 6 Expression of activating NK cell receptors before and after IL-15 exposure. Cytokine stimulation upregulated the expression of NKG2D and NKp30, while
it decreased that of NKp46. The orange circles represent cells from healthy donors (n  6), and the purple squares represent cells from HIV-infected donors
(n  6). Wilcoxon matched-pairs signed-rank test. *, P  0.05.
Another important finding of our study is the demonstration that NK cells obtained
correlated with NK cell frequency after panobinostat treatment in a clinical study (23), 
suggesting a role for NK cells in the clearance of HIV infection. Moreover, recent data 
suggest that NK cells might play an important role in viral clearance in the lymph node 
(16). However, until now, the ability of NK cells to clear latent HIV infection and the 
effect of cytokine treatment on this NK cell antiviral activity have not been reported.
Soluble recombinant human IL-15 (rhIL-15), the cytokine used in the present work, 
is sufficient for ex vivo proof-of-concept studies. However, research in oncology has 
brought into clinical testing several engineered forms of this potent cytokine, including 
a heterodimeric form of the molecule (24) and a synthetic receptor superagonist 
(ALT-803) (25), that might have better profiles for clinical use. The latter form of IL-15 
has been studied in the simian immunodeficiency virus model of HIV infection, ex-
panding both NK and CD8 T cells (26). Future directions could also include the 
incorporation of the IL-15 gene into genetically modified NK cells, so that the cells 
could provide autocrine cytokine support (27, 28). Moreover, it is expected that 
additional strategies will be needed to further enhance NK cell function, since in most 
of our results, despite seeing a robust antiviral effect of the stimulated NK cells, total 
clearance was not always observed. Thus, NK cell function might be improved by using 
other priming strategies, such as IFN- stimulation (29, 30) or therapeutic vaccination 
(31). In addition, clinical experience gained in oncology may be leveraged to design 
HIV-specific approaches, given the more advanced stages of NK cell-based therapies 
that have been developed for cancer (32–36).
The most relevant experiment in this study is undoubtedly the latency clearance 
assay (19) performed on primary resting CD4 T cells from HIV-infected individuals on 
antiretroviral treatment. This assay is the most proximate to the in vivo situation, 
eliminating artifacts produced by cell models or in vitro infections. As latency reversal 
was induced by VOR at exposures that have been safely achieved in clinical trials, it is 
likely that NK cell targeting and clearance can be similarly achieved in vivo.
Here, we proved that NK cells can clear infected cells after VOR exposure. However, 
a range of novel approaches to achieve HIV latency reversal are under study (37, 38). 
Thus, in a similar way, future work must address the effect of novel latency-reversing 
agents (LRAs) on NK-mediated clearance, given that antigen presentation or ligand 
modulation might be altered by host-targeted LRAs (39). Of interest, there is evidence 
that HDAC inhibitor exposure upregulates the surface expression of ligands for acti-
vating receptors in NK cells (40, 41). Nonetheless, while such upregulation is observed 
in tumor cells, the effect of LRA on latently HIV-infected cells is unknown. For example, 
valproic acid, a weak HDAC inhibitor, upregulates NKG2D ligands only in malignant 
cells, where the ligands are present at baseline (42). However, initial in vitro studies in 
HIV-infected cell lines suggested that VOR could also upregulate certain NKG2D ligands 
(43), which in addition may play an important role in facilitating NK-mediated ADCC 
responses (44). Finally, novel latency-reversing agents, such as Toll-like receptor (TLR) 
agonists, may simultaneously reverse HIV latency and improve NK cell function (45, 46), 
although further study is needed to definitively determine the effect of TLR agonists on 
NK cells, given the multiple and direct effects that these drugs might have on immune 
cells.
In addition to latency clearance assays, we conducted virus inhibition assays in the 
setting of active replication using a completely autologous system with NK cells, CD4 
T cells, and reservoir virus from the same donor. The use of patient-derived viral isolates 
is relevant, given that viruses may differ in antigen presentation. In our studies, we 
observed similar NK cell-mediated viral replication inhibition after infection with either 
JR-CSF or autologous reservoir virus. However, in the future, should ADCC be employed 
to direct NK cell killing, the breadth of antibody recognition of viral species within the 
latent reservoir may be critical.
In that regard, we also proved that IL-15 enhanced the ADCC activity of NK cells. 
Ongoing work seeks to identify antibodies or antibody combinations that will broadly 
recognize infected cells, specifically after latency reversal (47).
from HIV-positive donors on ART with suppressed viremia were sufficiently functional
to respond to IL-15 and exerted antiviral activity in all the assays performed. Interest-
ingly, we observed that IFN- production by HIV-positive donors was impaired com-
pared to that by HIV-negative individuals, but IL-15 stimulation restored IFN- produc-
tion in NK cells from HIV-positive donors to the level of HIV-negative donors. In fact,
IL-15-mediated improvement in the HIV-positive population was more pronounced
than in the HIV-negative group. The functionality of NK cells from HIV individuals with
virus suppressed has been previously described (48, 49), but our studies further
demonstrate their capability to be stimulated by IL-15 and to be functional in an HIV
eradication context.
Finally, we observed that NKG2D and NKp30 were upregulated after IL-15 treatment,
which may have contributed to the enhancement of NK cell function. We also observed
a downmodulation of NKp46 upon IL-15 exposure. This is in accordance with previous
reports (50) and is troublesome, given the importance of this receptor in NK cell
antiviral activity (22, 51, 52). Therefore, and even if we observed an important improve-
ment in NK cell function despite NKp46 downmodulation, it might be of interest to
consider a complementary strategy to boost NKp46 expression, thus further increasing
NK cell antiviral function.
In summary, the present study provides robust evidence that IL-15-stimulated NK
cells from virus-suppressed HIV-positive individuals on ART can recognize and clear
latently HIV-infected resting CD4 T cells after relevant exposure to the HDAC inhibitor
vorinostat. This finding encourages further exploration of approaches for immunother-
apies based on priming NK cells to eradicate latent HIV infection.
MATERIALS AND METHODS
Study samples. Samples were derived either from HIV-negative donors or from HIV-infected donors 
on ART with sustained plasma viremia suppression (50 copies/ml) for at least 6 months. In summary, 
the mean age of donors was 42.5 (SEM, 3.1) years, with suppressed viremia for an average of 3.4 (SEM, 
0.48) years, a mean total of 743 (SEM, 62) CD4 cells/ml, and a mean of 39.8% (SEM, 2.1%) CD4 cells. 
Peripheral blood mononuclear cells (PBMC) from HIV-negative donors were obtained from buffy coats 
from the New York Blood Center (Long Island City, NY, USA). PBMC from HIV-infected donors were 
obtained by Ficoll gradient from buffy coats obtained by leukapheresis. K562 cells were obtained from 
the ATCC (Manassas, VA).
Ethics statement. All donors provided written informed consent, and studies were approved by the 
University of North Carolina (UNC) Institutional Review Board. Samples used in the study were anony-
mized.
Virus inhibition assays. NK cells and CD4 T cells were isolated from the PBMC by negative 
selection (StemCell Technologies, Vancouver, Canada). The NK cell enrichment antibody cocktail included 
CD3, CD4, CD14, CD19, CD20, CD36, CD66b, CD123, HLA-DR, and glycophorin. CD4 T cells were isolated 
by negative selection in parallel with NK cell isolation from each donor. The CD4 T cell enrichment 
antibody cocktail included CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, T cell receptor /
(TCR-/), and glycophorin A. After isolation, NK cells were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM) supplemented with 10% heat-inactivated bovine serum and 5% penicillin plus strep-
tomycin, with or without the appropriate cytokines, for 24 h, after which the cells were washed and 
assays were performed. Isolated CD4 T cells were activated for 24 h with 2 g/ml PHA (Sigma-Aldrich, 
St. Louis, MO) and 60 U/ml IL-2 (Peprotech, Rocky Hill, CT). The cells were then infected by spinoculation 
for 90 min at 2,500 rpm with 50 ng HIV p24 per 10 million cells of the viral strain JR-CSF or with AR, which 
is virus isolated from a previous viral outgrowth assay performed with cells from the same donor (19). 
After spinoculation, the cells were extensively washed to remove free virions, and 50,000 infected CD4 
T cells were plated in triplicate for each condition in a 96-well plate. NK cells, previously exposed to 
cytokines when appropriate, were added to the wells at E:T ratios of 1:1, 1:10, and 1:100 and left in culture 
for 7 days in complete IMDM with 5 U/ml IL-2; the media were refreshed at day 4. Viral production was 
assessed in the supernatant by HIV p24 ELISA (ABL, Inc., Rockville, MD), and HIV replication under the 
different NK cell conditions was compared to replication with only target cells. Viral inhibition was also 
assessed by measuring intracellular p24 in cells harvested after 5 days of culture. For intracellular 
quantification of p24, cultures included a total of 800,000 cells, plated in eight replicates, which were 
pooled to perform the intracellular staining. The cells were first stained with the viability dye Zombie NIR 
Fixable Viability (Biolegend, San Diego, CA), fixed with 4% paraformaldehyde/lysolecithin, and then 
resuspended in cold 50% methanol, permeabilized with 0.1% Nonidet P-40, and stained with antibody 
for p24 Ag (KC-57, Beckman Coulter, Fullerton, CA), followed by surface staining with anti-CD3, -CD4, and 
-CD56. Infection was recorded as the percentage of viable CD3 CD4 cells expressing p24. Finally, we 
visualized the cells from one of these intracellular p24 experiments using the Amnis ImageStreamX Mark 
II (Millipore Sigma, St. Louis, MO), and analyzed the images with Ideas V6.2.187.0 software.
Cytotoxicity. NK cell cytotoxicity and IFN- production were analyzed in cocultures of primary NK 
cells and K562 cells (an NK-sensitive target cell line, due to their lack of MHC) with and without prior 
exposure of the NK cells to cytokines. Cytotoxicity was assessed by measurement of the degranulation 
marker CD107a, a reliable marker of NK cell functional activity (53). A total of 200,000 NK cells were 
cultured with the same number of K562 target cells, along with PE/Cy7-CD107a antibody (Biolegend, San 
Diego, CA), for 2 to 4 h in a 96-well plate, adding 1 l of GolgiStop (Becton Dickinson, Franklin Lakes, NJ) 
after 1 h. Cells were then harvested, washed, and stained with CD56-FITC and CD3-APC/Fire750 
(BioLegend) in staining buffer for 20 min on ice in the dark. The cells were then fixed with fixation buffer 
for 20 min at room temperature in the dark, permeabilized, and washed with Perm/Wash buffer 
(Biolegend, San Diego, CA) twice and stained with IFN-–PE (BioLegend) for 20 min. After washing, the 
cells were resuspended in staining buffer and analyzed in an Attune focusing cytometer (Applied 
Biosystems, Foster City, CA). To evaluate HIV-specific recognition, autologous CD4 T cells superinfected 
with the viral strain JR-CSF were used as targets, instead of the cell line K562. Additionally, NK cell 
degranulation was assessed in the absence of any target to examine nonspecific activation by cytokines. 
The activation conditions consisted of 25 ng/ml IL-15, but in some experiments, 25 ng/ml IL-12, 25 ng/ml 
IL-18, and/or 25 ng/ml IL-21 (Peprotech, Rocky Hill, NJ) was also used.
ADCC assay. We utilized a modified version of a previously published ADCC luciferase procedure 
(54). Briefly, CEM.NKRCCR5 cells (from A. Trkola, NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH 
[55]) were used as targets for ADCC luciferase assays after infection with subtype C HIV-1 IMCTV1 
(GenBank accession no. HM215437). Purified NK cells were obtained from six HIV-seronegative donors 
and six ART-treated HIV-seropositive donors. The NK cells were isolated from cryopreserved PBMC by 
negative selection with magnetic beads (Miltenyi Biotec GmbH, Germany) after overnight incubation 
with or without 10 ng/ml IL-15 (Miltenyi Biotec GmbH, Germany). The NK cells were used as effector cells 
at an effector-to-target cell ratio of 5:1. Target and effector cells were plated in opaque 96-well half-area 
plates and cocultured with serial dilutions of plasma (A300) from an HIV-infected donor starting at 1:100. 
The cocultures were incubated for 6 h at 37°C in 5% CO2. The final readout was the luminescence 
intensity generated by the presence of residual intact target cells that had not been lysed by the effector 
population in the presence of ADCC-mediating plasma Abs. The percentage of killing was calculated 
using the following formula: percent specific killing  [(RLU of target and effector well  RLU of test 
well)/(RLU of target and effector well)]  100, where RLU is relative light units.
In this analysis, the RLU of the target plus effector wells represent spontaneous lysis in the absence 
of any source of Ab. Plasma from an HIV-seronegative donor (CAVD002) was used as a negative control 
using the same dilution scheme. The data are reported as percent specific killing observed with the A300 
plasma after subtracting the background observed in the presence of the negative control, and the areas 
under the curve were calculated using Prism 7 (version 7.0b; GraphPad Software).
Latency clearance assay. A modified viral outgrowth assay (56) was optimized to assess the ability 
of cytokine-treated NK cells to clear latently infected cells after reactivation. Resting CD4 T cells were 
negatively isolated (Stemcell Technologies, Vancouver, Canada) from HIV-infected, ART-treated individ-
uals with virus suppressed and were cultured for 24 h with antiretroviral drugs (10 nM raltegravir and 20 
nM efavirenz) to avoid new cycles of infection. The cells were then washed from the antiretrovirals and 
reactivated with maximal mitogen stimulation (2 g/ml PHA and 60 U/ml IL-2) or with vorinostat (335 
nM). After 24 h, the cells were washed and plated in 12-well plates at 1 million to 2 million cells per well 
(more cells were used if the donor was known to have a low frequency of latent infection). NK cells were 
added to the culture at an E:T ratio of 1:10, and 24 h later, allogeneic stimulated CD8-depleted PBMC 
(feeders) were added to the culture to propagate the infection. To confirm that virus recovery reduction 
in the presence of NK cells was due to recognition of reactivated CD4 T cells and not to nonspecific 
killing or inhibition of viral spread, we conducted experiments in which we depleted the cultures of 
CD56 cells (CD56 positive-selection kit; StemCell Technologies) before adding the feeder cells. In either 
case, the cells were cultured for 19 days, changing the medium every 3 days and adding feeder cells on 
day 8. The numbers of positive wells were noted based on p24 ELISAs performed in the supernatants of 
the cultures at day 15 and day 19, and conditions with and without effectors were compared. Addition-
ally, in some experiments, after the first 24 h of culture of the reactivated CD4 T cells with or without 
NK cells, cell death was analyzed by flow cytometry using annexin V (BioLegend) staining.
Activating receptor expression. A panel of NK cell activating receptors was analyzed by flow 
cytometry comparing untreated NK cells and cells exposed to IL-15. The following surface monoclonal 
antibodies were used, after staining with the viability dye Zombie Aqua: CD3-peridinin chlorophyll 
protein (PerCP), dsCD56-APC/Cy7, CD16-AF700, NKG2D-APC, NKp30-PE, NKp46-PE/Cy7, and DNAM-1–
FITC (Biolegend). Samples were analyzed on the Attune focusing cytometer (Applied Biosystems). The 
CD3 CD56 population was gated in the viable gate, and the expression of each of the receptors was 
analyzed using FlowJo (Ashland, OR) X software. Fluorescence minus one (FMO) gating controls for each 
antibody were used to define the gates.
Statistical analysis. Analysis was performed with GraphPad Prism v7. Comparisons between 
matched groups were analyzed using the nonparametric Wilcoxon signed-rank test. Statistical signifi-
cance was assigned when the P value was 0.05. Results are expressed as means and SEM.
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